![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Molecular Pharmacology, Vol 7, 632-644, Copyright © 1971 by the American Society for Pharmacology and Experimental Therapeutics
1 Departments of Pharmacology and Medicine and Division of Biology, Albert Einstein College of Medicine,
New York, New York 10461
The plant alkaloid camptothecin inhibits the synthesis of DNA and RNA in HeLa cells at concentrations that do not initially influence protein synthesis. DNA, isolated from cells inhibited by camptothecin, has a sedimentation constant of approximately 40 S under alkaline conditions, in contrast to the high molecular weight DNA found in untreated cells. Inhibition of RNA synthesis in intact cells is completely reversed by removing the antibiotic from the medium, while DNA synthesis is only partially reversed by this procedure. Camptothecin does not significantly inhibit activity of the DNA-dependent RNA polymerase isolated from Escherichia coli or of DNA and RNA polymerases prepared from HeLa cells. The structure-activity relationships of camptothecin and its analogues, as determined by their effects on nucleic acid synthesis in HeLa cells and on the sedimentation of DNA obtained from drug-treated cells, correspond closely to their activity in suppressing the growth of tumors in experimental animals. The inhibitory effects of camptothecin on nucleic acid synthesis may account for its chemotherapeutic properties, and the reversibility of the effects on RNA synthesis suggests that camptothecin may be a useful tool for the study of macromolecular synthesis in animal cells.
Note:
ACKNOWLEDGMENTS
We are grateful to Drs. M. Wall and M. C.
Wani for providing us with the samples of camptothecin and its analogues. We are indebted to
Drs. M. Wall, A. S. Kende, and J. Hurwitz for
helpful discussions, and thank Drs. D. Kessel and
M. Horwitz for informing us of their experimental
results prior to publication. Dr. M. T. Huang
determined the effects of camptothecin on leucine
incorporation in lysates prepared from rabbit
reticulocytes.
This article has been cited by other articles:
|
|
 |
|
  X. Chen, S. Zhong, X. Zhu, B. Dziegielewska, T. Ellenberger, G. M. Wilson, A. D. MacKerell Jr., and A. E. Tomkinson Rational Design of Human DNA Ligase Inhibitors that Target Cellular DNA Replication and Repair Cancer Res., May 1, 2008; 68(9): 3169 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Davis Profile of Susan Band Horwitz PNAS, July 5, 2006; 103(27): 10163 - 10165. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chatterjee, R. Digumarti, R. N. V. S. Mamidi, K. Katneni, V. V. Upreti, A. Surath, M. L. Srinivas, S. Uppalapati, S. Jiwatani, S. Subramaniam, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF-1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study J. Clin. Pharmacol., July 1, 2004; 44(7): 723 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Rowinsky, J. Rizzo, L. Ochoa, C. H. Takimoto, B. Forouzesh, G. Schwartz, L. A. Hammond, A. Patnaik, J. Kwiatek, A. Goetz, et al. A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies J. Clin. Oncol., January 1, 2003; 21(1): 148 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Staker, K. Hjerrild, M. D. Feese, C. A. Behnke, A. B. Burgin Jr., and L. Stewart The mechanism of topoisomerase I poisoning by a camptothecin analog PNAS, November 26, 2002; 99(24): 15387 - 15392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Janss, A. Maity, C.-B. Tang, R. J. Muschel, W. G. McKenna, L. Sutton, and P. C. Phillips Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin Neuro-oncol, January 1, 2001; 3(1): 11 - 21. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Johnson, P. E. Bryant, and N. J. Jones Isolation of camptothecin-sensitive Chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group Mutagenesis, July 1, 2000; 15(4): 367 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Bible, R. H. Bible Jr., T. J. Kottke, P. A. Svingen, K. Xu, Y.-P. Pang, E. Hajdu, and S. H. Kaufmann Flavopiridol Binds to Duplex DNA Cancer Res., May 1, 2000; 60(9): 2419 - 2428. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Stewart, G. C. Ireton, and J. J. Champoux A Functional Linker in Human Topoisomerase I Is Required for Maximum Sensitivity to Camptothecin in a DNA Relaxation Assay J. Biol. Chem., November 12, 1999; 274(46): 32950 - 32960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Winter and M. Weller Potentiation of CD95L-Induced Apoptosis of Human Malignant Glioma Cells by Topotecan Involves Inhibition of RNA Synthesis but Not Changes in CD95 or CD95L Protein Expression J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1374 - 1382. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. R. Redinbo, L. Stewart, P. Kuhn, J. J. Champoux, and W. G. Hol Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA Science, March 6, 1998; 279(5356): 1504 - 1513. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ohdo, T. Makinosumi, T. Ishizaki, E. Yukawa, S. Higuchi, S. Nakano, and N. Ogawa Cell Cycle-Dependent Chronotoxicity of Irinotecan Hydrochloride in Mice J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1383 - 1388. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. S. Park, E. J. Morris, L. A. Greene, and H. M. Geller G1/S Cell Cycle Blockers and Inhibitors of Cyclin-Dependent Kinases Suppress Camptothecin-Induced Neuronal Apoptosis J. Neurosci., February 15, 1997; 17(4): 1256 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U Raju, C Koumenis, M Nunez-Regueiro, and A Eskin Alteration of the phase and period of a circadian oscillator by a reversible transcription inhibitor Science, August 9, 1991; 253(5020): 673 - 675. [Abstract] [PDF]
|
|
|
|
|
|
J. H. Neale, P. D. Klinger, and B. W. Agranoff Camptothecin Blocks Memory of Conditioned Avoidance in the Goldfish Science, March 23, 1973; 179(4079): 1243 - 1246. [Abstract] [PDF]
|
|
|
|
|
|
G. C. Ireton, L. Stewart, L. H. Parker, and J. J. Champoux Expression of Human Topoisomerase I with a Partial Deletion of the Linker Region Yields Monomeric and Dimeric Enzymes That Respond Differently to Camptothecin J. Biol. Chem., August 11, 2000; 275(33): 25820 - 25830. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
